September 29, 2022
1 minute read
Ezzedine K, et al. Attach. Treatment burden in patients with vitiligo: results from the global VALIANT study. Presented at: Congress of the European Academy of Dermatology and Venereology; September 7-10, 2022; Milano.
Ezzedine declares to be a consultant for AbbVie, Incyte Corporation, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi and Viela Bio. Please see the poster for relevant financial information from all other authors.
MILAN – Vitiligo treatment was found to cause more stress in women than in men, and the burden of treatment was greater in people with darker skin than lighter skin, according to a study presented here.
“These results highlight the high burden that patients with vitiligo endure in terms of starting and continuing treatment, difficulty finding treatment, and frustration with treatment outcomes, which can lead patients to stop treatment”, Khalid Ezzedine, MD, PhD, and his colleagues wrote in a poster presented at the congress of the European Academy of Dermatology and Venereology.
The online cross-sectional survey included participants from 17 countries in Africa/Middle East, Asia, Australia, Brazil, Canada, Europe and the United States. Of the 3,541 patients involved in the study, 54.6% were male and 59.2% had Fitzpatrick or lighter skin types I through III. According to the poster, elevated BSA involvement was reported in 29% of patients, as measured by the self-report vitiligo extent score.
Participants with darker skin reported greater treatment burden than those with lighter skin or high body surface area. More women agree or strongly agree that cosmetics and self-tanners are expensive, that they protect themselves from the sun with sunscreen, and that the effects of treatments on their physical appearance cause stress .